Adverse drug reactions caused by drug-drug interactions reported to Croatian Agency for Medicinal Products and Medical Devices: a retrospective observational study

被引:29
|
作者
Skvrce, Nikica Miroevic [1 ]
Sarinic, Viola Macolic [1 ]
Mucalo, Iva [2 ]
Krnic, Darko [1 ]
Bozina, Nada [3 ,4 ]
Tomic, Sinisa
机构
[1] Agcy Med Prod & Med Devices, Pharmacovigilance Dept, Zagreb, Croatia
[2] Univ Zagreb, Ctr Appl Chem, Fac Pharm & Biochem, Zagreb 41000, Croatia
[3] Univ Sch Med, Dept Lab Diagnost, Zagreb, Croatia
[4] Univ Hosp Ctr, Zagreb, Croatia
关键词
EMERGENCY-DEPARTMENT VISITS; HOSPITAL-ADMISSIONS; ELDERLY PATIENTS; CLINICAL-RELEVANCE; DETECTING SIGNALS; POTENTIAL RISKS; DATABASE; EVENTS; PREVENTION; PHARMACOVIGILANCE;
D O I
10.3325/cmj.2011.52.604
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim To analyze potential and actual drug-drug interactions reported to the Spontaneous Reporting Database of the Croatian Agency for Medicinal Products and Medical Devices (HALMED) and determine their incidence. Methods In this retrospective observational study performed from March 2005 to December 2008, we detected potential and actual drug-drug interactions using interaction programs and analyzed them. Results HALMED received 1209 reports involving at least two drugs. There were 468 (38.7%) reports on potential drug-drug interactions, 94 of which (7.8% of total reports) were actual drug-drug interactions. Among actual drug-drug interaction reports, the proportion of serious adverse drug reactions (53 out of 94) and the number of drugs (n = 4) was significantly higher (P < 0.001) than among the remaining reports (580 out of 1982; n = 2, respectively). Actual drug-drug interactions most frequently involved nervous system agents (34.0%), and interactions caused by antiplatelet, anticoagulant, and non-steroidal anti-inflammatory drugs were in most cases serious. In only 12 out of 94 reports, actual drug-drug interactions were recognized by the reporter. Conclusion The study confirmed that the Spontaneous Reporting Database was a valuable resource for detecting actual drug-drug interactions. Also, it identified drugs leading to serious adverse drug reactions and deaths, thus indicating the areas which should be in the focus of health care education.
引用
收藏
页码:604 / 614
页数:11
相关论文
共 50 条
  • [31] Adverse reactions of immune checkpoint inhibitors combined with angiogenesis inhibitors: A pharmacovigilance analysis of drug-drug interactions
    Ren, Xiayang
    Deng, Lei
    Dong, Xin
    Bai, Ying
    Li, Guohui
    Wang, Yanfeng
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2024, 38
  • [32] A descriptive analysis of drug-drug interactions and corresponding adverse drug reactions in multimorbid older inpatients: findings from the SENATOR trial
    Simal, Ine
    Somers, Annemie
    Amrouch, Cheima
    Capiau, Andreas
    Cherubini, Antonio
    Cruz-Jentoft, Alfonso J.
    Gudmundsson, Adalsteinn
    Soiza, Roy L.
    O.'Mahony, Denis
    Petrovic, Mirko
    EUROPEAN GERIATRIC MEDICINE, 2024, : 1357 - 1367
  • [33] Spontaneous Reports of Serious Adverse Drug Reactions Resulting From Drug-Drug Interactions: An Analysis From the French Pharmacovigilance Database
    Letinier, Louis
    Ferreira, Amandine
    Marceron, Alexandre
    Babin, Marina
    Micallef, Joelle
    Miremont-Salame, Ghada
    Pariente, Antoine
    FRONTIERS IN PHARMACOLOGY, 2021, 11
  • [34] Audit of drug-drug interactions and adverse drug reactions due to polypharmacy in older cancer patients: First report from India
    Paul, Thomas
    Palatty, Princy L.
    Adnan, Mohammed
    George, Thomas
    Rao, Suresh
    Baliga, Manjeshwar S.
    INDIAN JOURNAL OF CANCER, 2020, 57 (04) : 405 - 410
  • [35] Characterization of adverse drug reactions involving drug-drug interactions: 3 years of adverse drug reactions reporting by the APHM teaching hospitals to the Regional Center of Pharmacovigilance of Marseille-Provence-Corse
    Kheloufi, F.
    Default, A.
    Gervoise, M. Boyer
    Castellan, D.
    Rodrigues, B.
    Jean-Pastor, M. J.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2014, 28 : 55 - 55
  • [36] Adverse drug reactions reported with medical cannabis during the French Experimentation
    Chevallier, C.
    Chretien, B.
    Batisse, A.
    Ledys, F.
    Monzon, E.
    Richard, N.
    Benkebil, M.
    Vial, T.
    Auffret, M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 131 - 131
  • [37] Determination of potential drug-drug interactions in prescription orders dispensed in a community pharmacy setting using Micromedex® and Lexicomp®: a retrospective observational study
    Abbas, Afraa
    Al-Shaibi, Samaher
    Sankaralingam, Sowndramalingam
    Awaisu, Ahmed
    Kattezhathu, Vyas S.
    Wongwiwatthananukit, Supakit
    Owusu, Yaw B.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (02) : 348 - 356
  • [38] The importance of drug–drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France
    Francois Montastruc
    Agnès Sommet
    Emmanuelle Bondon-Guitton
    Geneviève Durrieu
    Eric Bui
    Haleh Bagheri
    Maryse Lapeyre-Mestre
    Laurent Schmitt
    Jean-Louis Montastruc
    European Journal of Clinical Pharmacology, 2012, 68 : 767 - 775
  • [39] Evaluation of potential drug-drug interactions and adverse drug reactions among chronic kidney disease patients: An experience from United Arab Emirates
    Hammoud, Kowsar Mouhib
    Sridhar, Sathvik B.
    Rabbani, Syed Arman
    Kurian, Martin Thomas
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2022, 21 (04) : 853 - 861
  • [40] Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study
    de Vries, Sieta T.
    Denig, Petra
    Ekhart, Corine
    Burgers, Jako S.
    Eefstra, Nanno K.
    Mol, Peter G. M.
    van Puijenbroek, Eugene P.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (07) : 1507 - 1515